Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $526.19 +0.73%
Revenue Growth %: +10.7%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +10.7%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.60, $0.11 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.2 billion versus the consensus estimate of $2.13 billion.
GUIDANCE:
Vertex Pharma raises FY2022 revenue to $8.6-8.8 billion, versus the consensus of $8.58 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
